Free Trial

Thermo Fisher Scientific (TMO) Financials

Thermo Fisher Scientific logo
$479.48 -11.93 (-2.43%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$482.50 +3.02 (+0.63%)
As of 09/12/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Thermo Fisher Scientific

Annual Income Statements for Thermo Fisher Scientific

This table shows Thermo Fisher Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
1,894 1,975 2,022 2,225 2,938 3,696 6,375 7,725 6,950 5,995 6,335
Consolidated Net Income / (Loss)
1,894 1,975 2,022 2,225 2,938 3,698 6,377 7,728 6,960 5,955 6,338
Net Income / (Loss) Continuing Operations
1,896 1,980 2,025 2,228 2,938 3,698 6,377 7,728 6,960 5,955 6,338
Total Pre-Tax Income
2,087 1,936 2,024 2,429 3,262 4,072 7,230 8,841 7,835 6,298 7,037
Total Operating Income
2,503 2,336 2,458 2,960 3,783 4,594 7,794 10,028 8,393 6,859 7,337
Total Gross Profit
7,492 7,756 8,372 9,448 10,857 11,328 16,004 19,638 18,971 17,100 17,702
Total Revenue
16,890 16,965 18,274 20,918 24,358 25,542 32,218 39,211 44,915 42,857 42,879
Operating Revenue
16,890 16,965 18,274 20,918 24,358 25,542 32,218 39,211 44,915 42,857 42,879
Total Cost of Revenue
9,398 9,209 9,902 11,470 13,501 14,214 16,214 19,573 25,944 25,757 25,177
Operating Cost of Revenue
9,398 9,209 9,902 11,470 13,501 14,214 16,214 19,573 25,944 25,757 25,177
Total Operating Expenses
4,989 5,420 5,914 6,488 7,074 6,734 8,210 9,610 10,578 10,241 10,364
Selling, General & Admin Expense
4,896 4,612 4,971 5,504 6,057 6,144 6,930 8,007 8,993 8,445 8,595
Research & Development Expense
691 692 754 887 967 1,003 1,181 1,406 1,471 1,337 1,390
Restructuring Charge
-598 116 189 97 50 -413 99 197 114 459 379
Total Other Income / (Expense), net
-416 -400 -434 -531 -521 -522 -564 -1,187 -558 -561 -300
Interest Expense
- - - 592 667 676 553 536 726 1,375 1,390
Interest & Investment Income
- - - 81 137 224 65 43 272 879 1,078
Other Income / (Expense), net
-416 -400 -434 -20 9.00 -70 -76 -694 -104 -65 12
Income Tax Expense
192 -44 -1.00 201 324 374 850 1,109 703 284 657
Other Gains / (Losses), net
- - - - - 0.00 -3.00 -4.00 -172 -59 -42
Net Income / (Loss) Attributable to Noncontrolling Interest
- - - - - 2.00 2.00 3.00 10 -40 3.00
Basic Earnings per Share
$4.76 $4.96 $5.12 $5.64 $7.31 $9.24 $16.09 $19.62 $17.75 $15.52 $16.58
Weighted Average Basic Shares Outstanding
398.20M 399M 395M 395M 402M 400M 396M 394M 392M 386M 382M
Diluted Earnings per Share
$4.71 $4.92 $5.09 $5.59 $7.24 $9.17 $15.96 $19.46 $17.63 $15.45 $16.53
Weighted Average Diluted Shares Outstanding
402.30M 402M 397M 398M 406M 403M 399M 397M 394M 388M 383M
Weighted Average Basic & Diluted Shares Outstanding
398M 398.30M 394.90M 394.50M 401.90M 398.83M 393.79M 391.19M 385.43M 381.31M 377.26M
Cash Dividends to Common per Share
$0.60 $0.60 $0.60 $0.60 $0.68 $0.76 $0.88 $1.04 $1.20 $1.40 $1.56

Quarterly Income Statements for Thermo Fisher Scientific

This table shows Thermo Fisher Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 4/1/2023 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025
Net Income / (Loss) Attributable to Common Shareholders
1,576 1,289 1,361 1,715 1,630 1,328 1,548 1,630 1,829 1,507 1,617
Consolidated Net Income / (Loss)
1,574 1,292 1,362 1,695 1,606 1,331 1,553 1,629 1,825 1,511 1,618
Net Income / (Loss) Continuing Operations
1,574 1,292 1,362 1,695 1,606 1,331 1,553 1,629 1,825 1,511 1,619
Total Pre-Tax Income
1,777 1,363 1,430 1,765 1,740 1,589 1,765 1,742 1,941 1,620 1,709
Total Operating Income
1,861 1,563 1,578 1,864 1,854 1,663 1,820 1,838 2,016 1,716 1,834
Total Gross Profit
4,606 4,140 4,251 4,316 4,393 4,205 4,347 4,328 4,822 4,235 4,409
Total Revenue
11,450 10,710 10,687 10,574 10,886 10,345 10,541 10,598 11,395 10,364 10,855
Operating Revenue
11,450 10,710 10,687 10,574 10,886 10,345 10,541 10,598 11,395 10,364 10,855
Total Cost of Revenue
6,844 6,570 6,436 6,258 6,493 6,140 6,194 6,270 6,573 6,129 6,446
Operating Cost of Revenue
6,844 6,570 6,436 6,258 6,493 6,140 6,194 6,270 6,573 6,129 6,446
Total Operating Expenses
2,745 2,577 2,673 2,452 2,539 2,543 2,527 2,489 2,805 2,518 2,574
Selling, General & Admin Expense
2,299 2,119 2,145 2,049 2,132 2,183 2,111 2,098 2,203 2,078 2,140
Research & Development Expense
391 346 345 319 327 331 339 346 374 342 352
Restructuring Charge
55 112 183 84 80 29 77 45 228 98 82
Total Other Income / (Expense), net
-84 -200 -148 -99 -114 -74 -54 -95 -77 -97 -126
Interest Expense
269 300 326 359 390 363 354 356 317 303 404
Interest & Investment Income
150 146 178 246 309 279 295 277 227 203 297
Other Income / (Expense), net
35 -46 0.00 14 -33 10 5.00 -16 13 3.00 -19
Income Tax Expense
173 46 52 53 133 281 128 99 149 95 92
Other Gains / (Losses), net
-30 -25 -16 -17 -1.00 23 -84 -14 33 -14 2.00
Net Income / (Loss) Attributable to Noncontrolling Interest
-2.00 3.00 1.00 -20 -24 4.00 6.00 0.00 -7.00 4.00 2.00
Basic Earnings per Share
$4.02 $3.34 $3.53 $4.44 $4.21 $3.47 $4.05 $4.26 $4.80 $3.99 $4.28
Weighted Average Basic Shares Outstanding
392M 386M 386M 386M 386M 382M 382M 382M 382M 378M 378M
Diluted Earnings per Share
$4.01 $3.32 $3.51 $4.42 $4.20 $3.46 $4.04 $4.25 $4.78 $3.98 $4.28
Weighted Average Diluted Shares Outstanding
394M 388M 388M 388M 388M 384M 383M 384M 383M 379M 378M
Weighted Average Basic & Diluted Shares Outstanding
385.43M 385.72M 385.95M 386.37M 381.31M 381.72M 382.00M 382.50M 377.26M 377.49M 377.61M
Cash Dividends to Common per Share
- $0.35 $0.35 $0.35 - $0.39 $0.39 $0.39 - $0.43 $0.43

Annual Cash Flow Statements for Thermo Fisher Scientific

This table details how cash moves in and out of Thermo Fisher Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents
-4,254 -898 345 130 1,053 305 7,914 -5,845 4,046 -440 -4,057
Net Cash From Operating Activities
2,620 2,942 3,258 4,005 4,543 4,973 8,289 9,312 9,154 8,406 8,667
Net Cash From Continuing Operating Activities
2,624 2,951 3,260 4,006 4,543 4,973 8,289 9,312 9,154 8,406 8,667
Net Income / (Loss) Continuing Operations
1,896 1,980 2,025 2,228 2,938 3,698 6,377 7,728 6,960 5,955 6,338
Consolidated Net Income / (Loss)
1,894 1,975 2,022 2,225 2,938 3,698 6,377 7,728 6,960 5,955 6,338
Depreciation Expense
1,685 1,688 1,758 439 526 564 658 831 986 1,068 1,156
Amortization Expense
- - - 1,594 1,741 1,713 1,667 1,761 2,395 2,338 1,952
Non-Cash Adjustments To Reconcile Net Income
-487 155 232 149 194 -85 438 1,374 462 1,092 602
Changes in Operating Assets and Liabilities, net
-404 -872 -755 -404 -856 -917 -851 -2,382 -1,649 -2,047 -1,381
Net Cash From Investing Activities
-11,920 -1,093 -5,520 -7,729 -1,253 -1,487 -1,510 -21,932 -2,159 -5,142 -5,841
Net Cash From Continuing Investing Activities
-11,920 -1,093 -5,520 -7,729 -1,253 -1,487 -1,510 -21,932 -2,159 -5,142 -5,841
Purchase of Property, Plant & Equipment
-428 -423 -444 -508 -758 -926 -1,474 -2,523 -2,243 -1,479 -1,400
Acquisitions
-13,060 -695 -5,178 -7,226 -536 -1,843 -38 -19,395 -39 -3,660 -3,132
Purchase of Investments
- - - - - - - - -52 -208 -3,396
Sale of Property, Plant & Equipment
49 18 26 7.00 50 36 8.00 20 24 87 57
Sale and/or Maturity of Investments
- 12 - - - - - - 116 15 1,770
Other Investing Activities, net
-3.30 -5.00 76 -2.00 -9.00 118 -6.00 -34 35 103 260
Net Cash From Financing Activities
4,980 -2,617 2,759 3,854 -2,237 -3,118 959 6,581 -2,810 -3,622 -6,792
Net Cash From Continuing Financing Activities
4,980 -2,617 2,759 3,854 -2,237 -3,118 959 6,581 -2,810 -3,622 -6,791
Repayment of Debt
-4,475 -11,680 -12,626 -11,816 -7,357 -9,893 -1,051 -11,673 -4,074 -7,661 -3,412
Repurchase of Common Equity
0.00 -500 -1,250 -750 -500 -1,500 -1,500 -2,000 -3,000 -3,000 -4,000
Payment of Dividends
-235 -241 -238 -237 -266 -297 -337 -395 -455 -523 -583
Issuance of Debt
6,592 9,732 16,786 14,839 5,750 8,419 3,847 20,649 4,719 7,562 1,204
Effect of Exchange Rate Changes
- -130 -152 - - -63 176 194 -139 -82 -91

Quarterly Cash Flow Statements for Thermo Fisher Scientific

This table details how cash moves in and out of Thermo Fisher Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 4/1/2023 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025
Net Change in Cash & Equivalents
5,603 -5,037 -347 3,015 1,929 -2,578 1,578 -2,427 -630 132 431
Net Cash From Operating Activities
3,487 729 1,540 2,414 3,723 1,251 1,960 2,166 3,290 723 1,399
Net Cash From Continuing Operating Activities
3,487 729 1,540 2,414 3,723 1,250 1,963 2,163 3,291 722 1,401
Net Income / (Loss) Continuing Operations
1,574 1,292 1,362 1,695 1,606 1,331 1,554 1,629 1,824 1,511 1,619
Consolidated Net Income / (Loss)
1,574 1,292 1,362 1,695 1,606 1,331 1,554 1,629 1,824 1,511 1,619
Depreciation Expense
256 253 270 269 276 285 277 290 304 276 256
Amortization Expense
592 606 585 584 563 551 514 449 438 429 430
Non-Cash Adjustments To Reconcile Net Income
-239 257 223 178 434 123 188 165 126 210 144
Changes in Operating Assets and Liabilities, net
1,304 -1,679 -900 -312 844 -1,040 -570 -370 599 -1,704 -1,048
Net Cash From Investing Activities
-525 -3,142 -443 -1,181 -376 -2,030 -253 -3,578 20 -527 -288
Net Cash From Continuing Investing Activities
-525 -3,142 -443 -1,181 -376 -2,030 -253 -3,577 19 -526 -288
Purchase of Property, Plant & Equipment
-550 -458 -284 -332 -405 -347 -301 -272 -480 -362 -294
Purchase of Investments
- -2.00 -186 -12 -8.00 -1,758 -20 -287 -1,331 -264 -47
Sale of Property, Plant & Equipment
6.00 6.00 4.00 66 11 4.00 16 20 17 12 1.00
Other Investing Activities, net
-45 16 70 6.00 11 71 52 94 43 88 52
Net Cash From Financing Activities
2,391 -2,593 -1,456 1,855 -1,428 -1,821 -115 -1,190 -3,666 -102 -991
Net Cash From Continuing Financing Activities
2,391 -2,593 -1,456 1,855 -1,428 -1,820 -115 -1,190 -3,666 -102 -991
Repayment of Debt
20 -503 -1,914 -1,476 -3,768 110 35 -1,040 -2,517 -793 -829
Payment of Dividends
-117 -117 -135 -135 -136 -135 -149 -150 -149 -149 -162
Effect of Exchange Rate Changes
250 -31 12 -73 10 22 -15 175 -273 37 311

Annual Balance Sheets for Thermo Fisher Scientific

This table presents Thermo Fisher Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets
42,852 40,834 45,908 56,669 56,232 58,381 69,052 95,123 97,154 98,726 97,321
Total Current Assets
6,540 5,741 7,021 9,421 10,625 11,893 21,957 20,113 25,229 24,589 22,137
Cash & Equivalents
1,344 452 786 1,335 2,103 2,399 10,325 4,477 8,524 8,077 4,009
Short-Term Investments
- - - - - - - - - 3.00 1,561
Accounts Receivable
2,474 2,545 3,049 3,879 4,136 4,349 5,741 7,977 8,115 8,221 8,191
Inventories, net
1,860 1,992 2,213 2,971 3,005 3,370 4,029 5,051 5,634 5,088 4,978
Other Current Assets
560 534 595 1,236 1,381 1,775 1,862 2,608 2,956 3,200 3,399
Plant, Property, & Equipment, net
2,427 2,449 2,578 4,047 4,165 4,749 5,912 8,333 9,280 9,448 9,306
Total Noncurrent Assets
33,886 32,644 36,309 43,201 41,442 41,739 41,183 66,677 62,645 64,689 65,878
Goodwill
18,843 18,828 21,328 25,290 25,347 25,714 26,041 41,924 41,196 44,020 45,853
Intangible Assets
14,110 12,758 13,969 16,684 14,978 14,014 12,685 20,113 17,442 16,670 15,533
Other Noncurrent Operating Assets
933 1,058 1,012 1,227 1,117 2,011 2,457 4,640 4,007 3,999 4,492
Total Liabilities & Shareholders' Equity
42,852 40,834 45,908 56,669 56,232 58,381 69,052 95,123 97,154 98,726 97,321
Total Liabilities
22,304 19,484 24,368 31,256 28,646 28,706 34,535 54,146 53,006 51,884 47,650
Total Current Liabilities
5,350 4,146 4,866 7,048 6,147 6,197 10,304 13,436 17,010 14,012 13,332
Short-Term Debt
2,212 1,052 1,255 2,135 1,271 676 2,628 2,537 5,579 3,609 2,214
Accounts Payable
821 822 926 1,428 1,615 1,920 2,175 2,867 3,381 2,872 3,079
Current Deferred Revenue
312 318 486 719 - - - 2,655 2,601 2,689 2,852
Current Employee Benefit Liabilities
669 598 709 918 982 1,010 1,916 2,427 2,095 1,596 1,988
Other Current Liabilities
1,171 1,144 1,490 1,848 2,279 2,591 3,585 2,950 3,354 3,246 3,199
Total Noncurrent Liabilities
16,954 15,338 19,502 24,208 22,499 22,509 24,231 40,710 35,996 37,872 34,318
Long-Term Debt
12,352 11,420 15,372 18,873 17,719 17,076 19,107 32,333 28,909 31,308 29,061
Noncurrent Deferred & Payable Income Tax Liabilities
3,431 2,623 2,557 2,766 2,265 2,192 1,794 3,837 2,849 1,922 1,268
Other Noncurrent Operating Liabilities
1,172 1,295 1,573 2,569 2,515 3,241 3,330 4,540 4,238 4,642 3,989
Redeemable Noncontrolling Interest
- - - - - - - 122 116 118 120
Total Equity & Noncontrolling Interests
20,548 21,350 21,540 25,413 27,586 29,675 34,517 40,855 44,032 46,724 49,551
Total Preferred & Common Equity
20,548 21,350 21,540 25,413 27,586 29,675 34,507 40,793 43,978 46,735 49,584
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
20,548 21,350 21,540 25,413 27,586 29,675 34,507 40,793 43,978 46,735 49,585
Common Stock
11,882 12,213 12,555 14,605 15,053 15,498 16,016 16,613 17,184 17,728 18,406
Retained Earnings
10,407 12,142 13,927 15,914 18,696 22,092 28,116 35,431 41,910 47,364 53,102
Treasury Stock
-456 -1,008 -2,306 -3,103 -3,665 -5,236 -6,818 -8,922 -12,017 -15,133 -19,226
Accumulated Other Comprehensive Income / (Loss)
-1,285 -1,997 -2,636 -2,003 -2,498 -2,679 -2,807 -2,329 -3,099 -3,224 -2,697
Noncontrolling Interest
- - - - - - 10 62 54 -11 -33

Quarterly Balance Sheets for Thermo Fisher Scientific

This table presents Thermo Fisher Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 4/1/2023 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025
Total Assets
97,154 94,658 94,105 97,057 98,726 97,095 98,496 100,364 97,321 99,041 101,230
Total Current Assets
25,229 20,209 19,995 23,092 24,589 23,640 25,476 23,783 22,137 23,378 24,584
Cash & Equivalents
8,524 3,482 3,133 6,151 8,077 5,499 7,073 4,645 4,009 4,134 4,576
Short-Term Investments
- - - - 3.00 1,751 1,750 2,000 1,561 1,813 1,814
Accounts Receivable
8,115 7,922 8,019 8,370 8,221 7,931 7,943 8,255 8,191 8,455 8,594
Inventories, net
5,634 5,664 5,655 5,404 5,088 5,133 5,198 5,430 4,978 5,224 5,559
Other Current Assets
2,956 3,141 3,188 3,167 3,200 3,326 3,512 3,452 3,399 3,753 4,040
Plant, Property, & Equipment, net
9,280 9,354 9,292 9,167 9,448 9,324 9,282 9,412 9,306 9,331 9,635
Total Noncurrent Assets
62,645 65,095 64,818 64,798 64,689 64,132 63,739 67,168 65,878 66,332 67,012
Goodwill
41,196 43,140 43,273 43,583 44,020 43,843 43,843 46,726 45,853 46,493 47,249
Intangible Assets
17,442 17,972 17,437 17,091 16,670 16,048 15,519 16,262 15,533 15,323 15,148
Other Noncurrent Operating Assets
4,007 3,983 4,108 4,124 3,999 4,241 4,377 4,180 4,492 4,516 4,615
Total Liabilities & Shareholders' Equity
97,154 94,658 94,105 97,057 98,726 97,095 98,496 100,364 97,321 99,041 101,230
Total Liabilities
53,006 52,225 50,190 51,593 51,884 51,472 50,963 51,264 47,650 49,556 50,627
Total Current Liabilities
17,010 15,884 14,112 14,158 14,012 13,937 14,772 14,601 13,332 13,174 12,718
Short-Term Debt
5,579 6,122 4,814 4,795 3,609 4,451 5,121 4,116 2,214 2,819 2,214
Accounts Payable
3,381 2,798 2,423 2,508 2,872 2,555 2,547 2,606 3,079 3,049 2,980
Current Deferred Revenue
2,601 2,662 2,590 2,547 2,689 2,632 2,591 2,663 2,852 2,866 2,805
Current Employee Benefit Liabilities
2,095 1,307 1,310 1,460 1,596 1,314 1,495 1,823 1,988 1,419 1,518
Other Current Liabilities
3,354 2,995 2,975 2,848 3,246 2,985 3,019 3,393 3,199 3,022 3,200
Total Noncurrent Liabilities
35,996 36,341 36,078 37,435 37,872 37,535 36,191 36,663 34,318 36,382 37,909
Long-Term Debt
28,909 29,135 29,194 30,489 31,308 31,157 30,284 31,197 29,061 31,370 33,015
Noncurrent Deferred & Payable Income Tax Liabilities
2,849 2,976 2,842 2,620 1,922 1,811 1,516 1,123 1,268 1,041 624
Other Noncurrent Operating Liabilities
4,238 4,230 4,042 4,326 4,642 4,567 4,391 4,343 3,989 3,971 4,270
Redeemable Noncontrolling Interest
116 123 113 118 118 119 115 127 120 128 126
Total Equity & Noncontrolling Interests
44,032 42,310 43,802 45,346 46,724 45,504 47,419 48,972 49,551 49,357 50,476
Total Preferred & Common Equity
43,978 42,257 43,752 45,328 46,735 45,516 47,432 48,992 49,584 49,390 50,512
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
43,978 42,257 43,752 45,328 46,735 45,517 47,432 48,992 49,585 49,390 50,511
Common Stock
17,184 17,330 17,471 17,607 17,728 17,925 18,092 18,275 18,406 18,555 18,676
Retained Earnings
41,910 43,064 44,289 45,869 47,364 48,542 49,940 51,421 53,102 54,447 55,901
Treasury Stock
-12,017 -15,083 -15,084 -15,121 -15,133 -18,186 -18,187 -18,227 -19,226 -21,269 -21,269
Accumulated Other Comprehensive Income / (Loss)
-3,099 -3,054 -2,924 -3,027 -3,224 -2,764 -2,413 -2,477 -2,697 -2,343 -2,797
Noncontrolling Interest
54 53 50 18 -11 -12 -12 -20 -33 -33 -35

Annual Metrics And Ratios for Thermo Fisher Scientific

This table displays calculated financial ratios and metrics derived from Thermo Fisher Scientific's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics
- - - - - - - - - - -
Revenue Growth
29.02% 0.45% 7.72% 14.47% 16.45% 4.86% 26.14% 21.71% 14.55% -4.58% 0.05%
EBITDA Growth
62.63% -3.92% 4.36% 31.49% 21.84% 12.25% 47.67% 18.75% -2.15% -12.60% 2.52%
EBIT Growth
58.18% -7.24% 4.55% 45.26% 28.98% 19.30% 70.60% 20.94% -11.20% -18.04% 8.17%
NOPAT Growth
45.68% 5.10% 2.94% 10.40% 25.49% 22.45% 64.85% 27.52% -12.89% -14.27% 1.56%
Net Income Growth
48.78% 4.25% 2.38% 10.04% 32.04% 25.87% 72.44% 21.19% -9.94% -14.44% 6.43%
EPS Growth
35.34% 4.46% 3.46% 9.82% 29.52% 26.66% 74.05% 21.93% -9.40% -12.37% 6.99%
Operating Cash Flow Growth
30.28% 12.31% 10.74% 22.93% 13.43% 9.47% 66.68% 12.34% -1.70% -8.17% 3.10%
Free Cash Flow Firm Growth
-646.54% 127.92% -155.66% -221.58% 180.57% -10.03% 65.29% -378.87% 153.37% -66.48% 66.09%
Invested Capital Growth
56.97% -1.18% 12.02% 20.61% -1.36% 1.25% 2.00% 55.40% -1.76% 5.09% 2.30%
Revenue Q/Q Growth
6.47% 0.95% 1.67% 5.52% 1.92% 1.28% 13.06% 0.39% 1.69% -1.30% 1.20%
EBITDA Q/Q Growth
9.87% 1.14% 3.25% 18.58% 105.11% -5.38% 23.64% -7.29% 0.42% -0.82% 1.07%
EBIT Q/Q Growth
8.27% 2.39% 3.57% 30.03% 5.89% -8.22% 32.52% -9.84% -1.38% -1.09% 2.91%
NOPAT Q/Q Growth
15.61% -0.06% 0.76% -4.71% 13.31% 4.15% 27.14% -4.37% -7.18% 0.54% 2.30%
Net Income Q/Q Growth
15.84% 0.05% 1.38% -4.37% 14.41% 2.95% 30.65% -9.81% -1.21% 0.54% 3.58%
EPS Q/Q Growth
13.49% 0.41% 1.60% -5.09% 14.56% 3.27% 30.71% -9.61% -0.96% 1.25% 3.64%
Operating Cash Flow Q/Q Growth
9.41% 15.71% -4.34% 19.76% -1.41% 2.30% 20.78% -8.65% 12.68% 2.89% -4.76%
Free Cash Flow Firm Q/Q Growth
7.39% -12.23% 37.97% -10.81% -8.51% 5.24% 15.69% -370.76% 166.66% 58.16% 48.63%
Invested Capital Q/Q Growth
-1.96% -0.86% -3.16% -1.89% -0.21% -0.24% 1.21% 47.49% 0.21% -1.23% -3.07%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
44.36% 45.72% 45.81% 45.17% 44.57% 44.35% 49.67% 50.08% 42.24% 39.90% 41.28%
EBITDA Margin
22.33% 21.36% 20.70% 23.77% 24.87% 26.63% 31.17% 30.41% 25.98% 23.80% 24.39%
Operating Margin
14.82% 13.77% 13.45% 14.15% 15.53% 17.99% 24.19% 25.57% 18.69% 16.00% 17.11%
EBIT Margin
12.36% 11.41% 11.08% 14.05% 15.57% 17.71% 23.96% 23.80% 18.45% 15.85% 17.14%
Profit (Net Income) Margin
11.22% 11.64% 11.06% 10.64% 12.06% 14.48% 19.79% 19.71% 15.50% 13.90% 14.78%
Tax Burden Percent
90.76% 102.01% 99.90% 91.60% 90.07% 90.82% 88.20% 87.41% 88.83% 94.55% 90.07%
Interest Burden Percent
100.00% 100.00% 100.00% 82.62% 86.02% 90.01% 93.68% 94.72% 94.52% 92.70% 95.75%
Effective Tax Rate
9.18% -2.27% -0.05% 8.28% 9.93% 9.18% 11.76% 12.54% 8.97% 4.51% 9.34%
Return on Invested Capital (ROIC)
8.22% 7.12% 6.95% 6.58% 7.61% 9.32% 15.12% 14.95% 10.80% 9.11% 8.93%
ROIC Less NNEP Spread (ROIC-NNEP)
3.99% 3.84% 3.81% 3.82% 5.04% 6.38% 11.38% 9.97% 8.39% 6.86% 7.73%
Return on Net Nonoperating Assets (RNNOA)
1.91% 2.31% 2.48% 2.89% 3.48% 3.59% 4.75% 5.52% 5.55% 3.98% 4.21%
Return on Equity (ROE)
10.13% 9.43% 9.43% 9.48% 11.09% 12.92% 19.87% 20.47% 16.35% 13.09% 13.13%
Cash Return on Invested Capital (CROIC)
-36.12% 8.30% -4.39% -12.10% 8.98% 8.08% 13.15% -28.43% 12.58% 4.15% 6.65%
Operating Return on Assets (OROA)
5.59% 4.63% 4.67% 5.73% 6.72% 7.89% 12.11% 11.37% 8.62% 6.94% 7.50%
Return on Assets (ROA)
5.07% 4.72% 4.66% 4.34% 5.20% 6.45% 10.01% 9.41% 7.24% 6.08% 6.47%
Return on Common Equity (ROCE)
10.13% 9.43% 9.43% 9.48% 11.09% 12.92% 19.87% 20.42% 16.28% 13.05% 13.11%
Return on Equity Simple (ROE_SIMPLE)
9.22% 9.25% 9.39% 8.76% 10.65% 12.46% 18.48% 18.94% 15.83% 12.74% 12.78%
Net Operating Profit after Tax (NOPAT)
2,273 2,389 2,459 2,715 3,407 4,172 6,878 8,770 7,640 6,550 6,652
NOPAT Margin
13.46% 14.08% 13.46% 12.98% 13.99% 16.33% 21.35% 22.37% 17.01% 15.28% 15.51%
Net Nonoperating Expense Percent (NNEP)
4.24% 3.28% 3.14% 2.76% 2.57% 2.94% 3.74% 4.99% 2.41% 2.25% 1.20%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 9.73% 8.02% 8.23%
Cost of Revenue to Revenue
55.64% 54.28% 54.19% 54.83% 55.43% 55.65% 50.33% 49.92% 57.76% 60.10% 58.72%
SG&A Expenses to Revenue
28.99% 27.19% 27.20% 26.31% 24.87% 24.05% 21.51% 20.42% 20.02% 19.71% 20.04%
R&D to Revenue
4.09% 4.08% 4.13% 4.24% 3.97% 3.93% 3.67% 3.59% 3.28% 3.12% 3.24%
Operating Expenses to Revenue
29.54% 31.95% 32.36% 31.02% 29.04% 26.36% 25.48% 24.51% 23.55% 23.90% 24.17%
Earnings before Interest and Taxes (EBIT)
2,087 1,936 2,024 2,940 3,792 4,524 7,718 9,334 8,289 6,794 7,349
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3,772 3,624 3,782 4,973 6,059 6,801 10,043 11,926 11,670 10,200 10,457
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 2.54 2.95 3.22 4.34 5.31 6.41 4.88 4.38 4.01
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 2.99 3.58 3.65 5.05 5.68 6.66 4.78 4.77 4.64
Price to Earnings (P/E)
0.00 0.00 27.03 33.67 30.26 34.87 28.72 33.82 30.91 34.12 31.41
Dividend Yield
0.49% 0.43% 0.43% 0.32% 0.31% 0.24% 0.19% 0.16% 0.22% 0.26% 0.30%
Earnings Yield
0.00% 0.00% 3.70% 2.97% 3.30% 2.87% 3.48% 2.96% 3.24% 2.93% 3.18%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 1.89 2.10 2.38 3.20 4.24 4.09 3.44 3.14 2.98
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 3.86 4.52 4.34 5.65 6.04 7.44 5.36 5.40 5.24
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 18.64 19.02 17.46 21.21 19.37 24.47 20.65 22.69 21.50
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 34.83 32.17 27.90 31.88 25.20 31.27 29.07 34.07 30.59
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 28.67 34.84 31.05 34.57 28.28 33.28 31.54 35.34 33.79
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 21.64 23.62 23.29 29.01 23.47 31.34 26.32 27.54 25.94
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 26.32 39.88 32.53 0.00 27.08 77.60 45.37
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.71 0.58 0.77 0.83 0.69 0.60 0.63 0.85 0.78 0.75 0.63
Long-Term Debt to Equity
0.60 0.53 0.71 0.74 0.64 0.58 0.55 0.79 0.65 0.67 0.59
Financial Leverage
0.48 0.60 0.65 0.76 0.69 0.56 0.42 0.55 0.66 0.58 0.54
Leverage Ratio
2.00 2.00 2.02 2.18 2.13 2.00 1.99 2.17 2.26 2.15 2.03
Compound Leverage Factor
2.00 2.00 2.02 1.81 1.83 1.80 1.86 2.06 2.14 2.00 1.95
Debt to Total Capital
41.48% 36.88% 43.56% 45.26% 40.77% 37.43% 38.64% 45.97% 43.86% 42.71% 38.64%
Short-Term Debt to Total Capital
6.30% 3.11% 3.29% 4.60% 2.73% 1.43% 4.67% 3.34% 7.09% 4.41% 2.74%
Long-Term Debt to Total Capital
35.18% 33.77% 40.28% 40.66% 38.04% 36.00% 33.97% 42.63% 36.76% 38.29% 35.90%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.24% 0.22% 0.13% 0.11%
Common Equity to Total Capital
58.52% 63.12% 56.44% 54.74% 59.23% 62.57% 61.34% 53.78% 55.93% 57.16% 61.26%
Debt to EBITDA
3.86 3.44 4.40 4.22 3.13 2.61 2.16 2.92 2.96 3.42 2.99
Net Debt to EBITDA
3.50 3.32 4.19 3.96 2.79 2.26 1.14 2.55 2.22 2.63 2.46
Long-Term Debt to EBITDA
3.27 3.15 4.06 3.80 2.92 2.51 1.90 2.71 2.48 3.07 2.78
Debt to NOPAT
6.41 5.22 6.76 7.74 5.57 4.26 3.16 3.98 4.51 5.33 4.70
Net Debt to NOPAT
5.82 5.03 6.44 7.25 4.96 3.68 1.66 3.47 3.40 4.10 3.86
Long-Term Debt to NOPAT
5.43 4.78 6.25 6.95 5.20 4.09 2.78 3.69 3.78 4.78 4.37
Altman Z-Score
0.00 0.00 2.37 2.42 3.08 4.03 4.79 4.24 3.88 3.83 4.07
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.26% 0.42% 0.30% 0.20%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.22 1.38 1.44 1.34 1.73 1.92 2.13 1.50 1.48 1.75 1.66
Quick Ratio
0.71 0.72 0.79 0.74 1.02 1.09 1.56 0.93 0.98 1.16 1.03
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-9,983 2,788 -1,552 -4,990 4,020 3,617 5,979 -16,673 8,898 2,983 4,954
Operating Cash Flow to CapEx
692.47% 726.42% 779.43% 799.40% 641.67% 558.76% 565.42% 372.03% 412.53% 603.88% 645.35%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 -8.43 6.03 5.35 10.81 -31.11 12.26 2.17 3.56
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 6.77 6.81 7.36 14.99 17.37 12.61 6.11 6.24
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 5.92 5.75 6.04 12.34 12.70 9.55 5.10 5.27
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.45 0.41 0.42 0.41 0.43 0.45 0.51 0.48 0.47 0.44 0.44
Accounts Receivable Turnover
7.65 6.76 6.53 6.04 6.08 6.02 6.39 5.72 5.58 5.25 5.23
Inventory Turnover
5.60 4.78 4.71 4.43 4.52 4.46 4.38 4.31 4.86 4.80 5.00
Fixed Asset Turnover
8.05 6.96 7.27 6.31 5.93 5.73 6.04 5.51 5.10 4.58 4.57
Accounts Payable Turnover
12.43 11.21 11.33 9.75 8.87 8.04 7.92 7.76 8.30 8.24 8.46
Days Sales Outstanding (DSO)
47.72 53.99 55.87 60.44 60.05 60.63 57.16 63.85 65.39 69.56 69.85
Days Inventory Outstanding (DIO)
65.13 76.32 77.50 82.48 80.78 81.85 83.28 84.66 75.16 75.97 72.97
Days Payable Outstanding (DPO)
29.37 32.56 32.22 37.45 41.13 45.39 46.09 47.01 43.95 44.31 43.14
Cash Conversion Cycle (CCC)
83.48 97.75 101.14 105.47 99.70 97.09 94.34 101.50 96.60 101.23 99.68
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
33,769 33,370 37,381 45,086 44,473 45,028 45,927 71,370 70,112 73,679 75,377
Invested Capital Turnover
0.61 0.51 0.52 0.51 0.54 0.57 0.71 0.67 0.63 0.60 0.58
Increase / (Decrease) in Invested Capital
12,256 -399 4,011 7,705 -613 555 899 25,443 -1,258 3,567 1,698
Enterprise Value (EV)
0.00 0.00 70,497 94,588 105,793 144,246 194,513 291,872 240,951 231,470 224,780
Market Capitalization
0.00 0.00 54,656 74,915 88,906 128,893 183,093 261,295 214,817 204,526 198,988
Book Value per Share
$51.60 $53.51 $54.53 $63.37 $68.52 $74.00 $87.07 $103.52 $112.13 $120.96 $129.63
Tangible Book Value per Share
($31.15) ($25.65) ($34.83) ($41.30) ($31.64) ($25.07) ($10.65) ($53.91) ($37.38) ($36.12) ($30.85)
Total Capital
35,112 33,822 38,167 46,421 46,576 47,427 56,252 75,847 78,636 81,759 80,946
Total Debt
14,564 12,472 16,627 21,008 18,990 17,752 21,735 34,870 34,488 34,917 31,275
Total Long-Term Debt
12,352 11,420 15,372 18,873 17,719 17,076 19,107 32,333 28,909 31,308 29,061
Net Debt
13,221 12,020 15,841 19,673 16,887 15,353 11,410 30,393 25,964 26,837 25,705
Capital Expenditures (CapEx)
378 405 418 501 708 890 1,466 2,503 2,219 1,392 1,343
Debt-free, Cash-free Net Working Capital (DFCFNWC)
2,059 2,195 2,624 3,173 3,646 3,973 3,956 4,737 5,274 6,106 5,449
Debt-free Net Working Capital (DFNWC)
3,402 2,647 3,410 4,508 5,749 6,372 14,281 9,214 13,798 14,186 11,019
Net Working Capital (NWC)
1,190 1,595 2,155 2,373 4,478 5,696 11,653 6,677 8,219 10,577 8,805
Net Nonoperating Expense (NNE)
379 414 437 490 469 474 501 1,042 680 595 314
Net Nonoperating Obligations (NNO)
13,221 12,020 15,841 19,673 16,887 15,353 11,410 30,393 25,964 26,837 25,706
Total Depreciation and Amortization (D&A)
1,685 1,688 1,758 2,033 2,267 2,277 2,325 2,592 3,381 3,406 3,108
Debt-free, Cash-free Net Working Capital to Revenue
12.19% 12.94% 14.36% 15.17% 14.97% 15.55% 12.28% 12.08% 11.74% 14.25% 12.71%
Debt-free Net Working Capital to Revenue
20.14% 15.60% 18.66% 21.55% 23.60% 24.95% 44.33% 23.50% 30.72% 33.10% 25.70%
Net Working Capital to Revenue
7.05% 9.40% 11.79% 11.34% 18.38% 22.30% 36.17% 17.03% 18.30% 24.68% 20.53%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$4.76 $4.96 $5.12 $5.64 $7.31 $9.24 $16.09 $19.62 $17.75 $15.52 $16.58
Adjusted Weighted Average Basic Shares Outstanding
398.20M 398.70M 394.80M 395M 402M 400M 396M 394M 392M 386M 382M
Adjusted Diluted Earnings per Share
$4.71 $4.92 $5.09 $5.59 $7.24 $9.17 $15.96 $19.46 $17.63 $15.45 $16.53
Adjusted Weighted Average Diluted Shares Outstanding
402.30M 401.90M 397.40M 398M 406M 403M 399M 397M 394M 388M 383M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $9.24 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
396.78M 396.26M 390.39M 401.78M 399.00M 398.83M 393.79M 391.19M 385.43M 381.31M 377.26M
Normalized Net Operating Profit after Tax (NOPAT)
1,730 1,716 1,853 2,804 3,452 3,797 6,965 8,942 7,744 6,988 6,996
Normalized NOPAT Margin
10.24% 10.12% 10.14% 13.40% 14.17% 14.87% 21.62% 22.81% 17.24% 16.31% 16.31%
Pre Tax Income Margin
12.36% 11.41% 11.08% 11.61% 13.39% 15.94% 22.44% 22.55% 17.44% 14.70% 16.41%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 4.97 5.69 6.69 13.96 17.41 11.42 4.94 5.29
NOPAT to Interest Expense
0.00 0.00 0.00 4.59 5.11 6.17 12.44 16.36 10.52 4.76 4.79
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 4.12 4.62 5.38 11.31 12.74 8.36 3.93 4.32
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 3.74 4.05 4.86 9.79 11.69 7.47 3.75 3.82
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
12.39% 12.20% 11.77% 10.65% 9.05% 8.03% 5.28% 5.11% 6.54% 8.78% 9.20%
Augmented Payout Ratio
12.39% 37.52% 73.59% 44.36% 26.07% 48.59% 28.81% 30.99% 49.64% 59.16% 72.31%

Quarterly Metrics And Ratios for Thermo Fisher Scientific

This table displays calculated financial ratios and metrics derived from Thermo Fisher Scientific's official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 4/1/2023 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
6.99% -9.38% -2.58% -0.96% -4.93% -3.41% -1.37% 0.23% 4.68% 0.18% 2.98%
EBITDA Growth
1.82% -32.44% -15.08% 7.35% -3.06% 5.60% 7.52% -6.22% 4.17% -3.39% -4.40%
EBIT Growth
-5.77% -42.93% -22.23% 10.08% -3.96% 10.28% 15.65% -2.98% 11.42% 2.75% -0.55%
NOPAT Growth
-25.71% -39.27% -15.25% 7.82% 1.93% -9.36% 11.01% -4.12% 8.70% 18.00% 2.80%
Net Income Growth
-5.12% -41.80% -18.35% 13.15% 2.03% 3.02% 14.02% -3.89% 13.64% 13.52% 4.19%
EPS Growth
-4.07% -40.82% -16.82% 16.62% 4.74% 4.22% 15.10% -3.85% 13.81% 15.03% 5.94%
Operating Cash Flow Growth
41.92% -66.89% 0.79% 24.63% 6.77% 71.60% 27.27% -10.27% -11.63% -42.21% -28.62%
Free Cash Flow Firm Growth
112.67% 94.94% 88.13% 85.83% -163.13% 249.93% 197.39% 49.11% 108.80% -233.53% -252.04%
Invested Capital Growth
-1.76% 3.59% 5.57% 6.62% 5.09% -0.30% -0.90% 4.25% 2.30% 5.06% 7.19%
Revenue Q/Q Growth
7.24% -6.46% -0.21% -1.06% 2.95% -4.97% 1.89% 0.54% 7.52% -9.05% 4.74%
EBITDA Q/Q Growth
7.86% -13.41% 2.40% 12.25% -2.60% -5.68% 4.26% -2.10% 8.20% -12.52% 3.18%
EBIT Q/Q Growth
11.14% -19.99% 4.02% 19.01% -3.04% -8.13% 9.09% -0.16% 11.36% -15.28% 5.58%
NOPAT Q/Q Growth
0.17% -10.09% 0.69% 18.90% -5.30% -20.05% 23.31% 2.70% 7.37% -13.21% 7.42%
Net Income Q/Q Growth
5.07% -17.92% 5.42% 24.45% -5.25% -17.12% 16.68% 4.89% 12.03% -17.21% 7.08%
EPS Q/Q Growth
5.80% -17.21% 5.72% 25.93% -4.98% -17.62% 16.76% 5.20% 12.47% -16.74% 7.54%
Operating Cash Flow Q/Q Growth
80.02% -79.09% 111.25% 56.75% 54.23% -66.40% 56.67% 10.51% 51.89% -78.02% 93.50%
Free Cash Flow Firm Q/Q Growth
114.76% -136.21% -128.10% -16.26% 34.25% 185.99% 48.16% -160.75% 111.37% -1,404.58% -68.70%
Invested Capital Q/Q Growth
0.21% 5.84% 0.78% -0.26% -1.23% 0.41% 0.18% 4.93% -3.07% 3.12% 2.21%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
40.23% 38.66% 39.78% 40.82% 40.35% 40.65% 41.24% 40.84% 42.32% 40.86% 40.62%
EBITDA Margin
23.97% 22.18% 22.77% 25.83% 24.44% 24.25% 24.82% 24.16% 24.32% 23.39% 23.04%
Operating Margin
16.25% 14.59% 14.77% 17.63% 17.03% 16.08% 17.27% 17.34% 17.69% 16.56% 16.90%
EBIT Margin
16.56% 14.16% 14.77% 17.76% 16.73% 16.17% 17.31% 17.19% 17.81% 16.59% 16.72%
Profit (Net Income) Margin
13.75% 12.06% 12.74% 16.03% 14.75% 12.87% 14.73% 15.37% 16.02% 14.58% 14.91%
Tax Burden Percent
88.58% 94.79% 95.24% 96.03% 92.30% 83.76% 87.99% 93.51% 94.02% 93.27% 94.68%
Interest Burden Percent
93.72% 89.85% 90.62% 93.98% 95.55% 94.98% 96.71% 95.61% 95.66% 94.24% 94.16%
Effective Tax Rate
9.74% 3.37% 3.64% 3.00% 7.64% 17.68% 7.25% 5.68% 7.68% 5.86% 5.38%
Return on Invested Capital (ROIC)
9.31% 8.47% 8.50% 10.27% 9.38% 7.59% 9.11% 9.10% 9.40% 8.81% 9.00%
ROIC Less NNEP Spread (ROIC-NNEP)
8.94% 7.77% 7.97% 9.86% 8.97% 7.46% 8.64% 8.74% 9.26% 8.45% 8.57%
Return on Net Nonoperating Assets (RNNOA)
5.92% 5.79% 5.47% 6.12% 5.21% 5.10% 5.43% 5.34% 5.04% 5.03% 4.84%
Return on Equity (ROE)
15.23% 14.26% 13.97% 16.40% 14.58% 12.68% 14.54% 14.44% 14.44% 13.84% 13.84%
Cash Return on Invested Capital (CROIC)
12.58% 5.60% 3.35% 2.61% 4.15% 8.95% 9.74% 4.38% 6.65% 4.16% 2.11%
Operating Return on Assets (OROA)
7.74% 6.62% 6.96% 8.22% 7.32% 7.17% 7.61% 7.38% 7.79% 7.26% 7.24%
Return on Assets (ROA)
6.42% 5.64% 6.01% 7.42% 6.46% 5.70% 6.48% 6.60% 7.01% 6.38% 6.45%
Return on Common Equity (ROCE)
15.17% 14.20% 13.92% 16.34% 14.54% 12.64% 14.49% 14.40% 14.41% 13.81% 13.81%
Return on Equity Simple (ROE_SIMPLE)
0.00% 14.27% 13.09% 13.07% 0.00% 13.17% 13.04% 12.49% 0.00% 13.20% 0.00%
Net Operating Profit after Tax (NOPAT)
1,680 1,510 1,521 1,808 1,712 1,369 1,688 1,734 1,861 1,615 1,735
NOPAT Margin
14.67% 14.10% 14.23% 17.10% 15.73% 13.23% 16.01% 16.36% 16.33% 15.59% 15.99%
Net Nonoperating Expense Percent (NNEP)
0.38% 0.70% 0.54% 0.41% 0.40% 0.13% 0.47% 0.36% 0.14% 0.37% 0.42%
Return On Investment Capital (ROIC_SIMPLE)
2.14% - - - 2.10% - - - 2.30% 1.93% 2.02%
Cost of Revenue to Revenue
59.77% 61.34% 60.22% 59.18% 59.65% 59.35% 58.76% 59.16% 57.68% 59.14% 59.38%
SG&A Expenses to Revenue
20.08% 19.79% 20.07% 19.38% 19.58% 21.10% 20.03% 19.80% 19.33% 20.05% 19.71%
R&D to Revenue
3.41% 3.23% 3.23% 3.02% 3.00% 3.20% 3.22% 3.26% 3.28% 3.30% 3.24%
Operating Expenses to Revenue
23.97% 24.06% 25.01% 23.19% 23.32% 24.58% 23.97% 23.49% 24.62% 24.30% 23.71%
Earnings before Interest and Taxes (EBIT)
1,896 1,517 1,578 1,878 1,821 1,673 1,825 1,822 2,029 1,719 1,815
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,744 2,376 2,433 2,731 2,660 2,509 2,616 2,561 2,771 2,424 2,501
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.88 5.24 4.59 4.30 4.38 4.93 4.45 4.79 4.01 3.82 3.05
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
4.78 5.05 4.61 4.49 4.77 5.28 4.98 5.54 4.64 4.40 3.57
Price to Earnings (P/E)
30.91 36.75 35.08 32.80 34.12 37.19 33.93 38.25 31.41 28.97 23.41
Dividend Yield
0.22% 0.22% 0.25% 0.27% 0.26% 0.25% 0.27% 0.25% 0.30% 0.32% 0.40%
Earnings Yield
3.24% 2.72% 2.85% 3.05% 2.93% 2.69% 2.95% 2.61% 3.18% 3.45% 4.27%
Enterprise Value to Invested Capital (EV/IC)
3.44 3.41 3.10 3.00 3.14 3.42 3.21 3.39 2.98 2.79 2.30
Enterprise Value to Revenue (EV/Rev)
5.36 5.78 5.32 5.16 5.40 5.95 5.62 6.22 5.24 5.06 4.24
Enterprise Value to EBITDA (EV/EBITDA)
20.65 24.06 22.95 21.79 22.69 24.47 22.61 25.47 21.50 20.92 17.85
Enterprise Value to EBIT (EV/EBIT)
29.07 35.44 34.60 32.63 34.07 36.39 33.04 36.90 30.59 29.35 24.79
Enterprise Value to NOPAT (EV/NOPAT)
31.54 38.07 36.30 34.40 35.34 39.48 36.16 40.52 33.79 31.46 26.36
Enterprise Value to Operating Cash Flow (EV/OCF)
26.32 32.98 30.12 27.43 27.54 28.32 25.44 28.95 25.94 26.67 24.16
Enterprise Value to Free Cash Flow (EV/FCFF)
27.08 62.08 95.11 118.84 77.60 38.13 32.79 79.05 45.37 68.84 113.23
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.78 0.83 0.77 0.78 0.75 0.78 0.74 0.72 0.63 0.69 0.70
Long-Term Debt to Equity
0.65 0.69 0.66 0.67 0.67 0.68 0.64 0.64 0.59 0.63 0.65
Financial Leverage
0.66 0.75 0.69 0.62 0.58 0.68 0.63 0.61 0.54 0.60 0.56
Leverage Ratio
2.26 2.24 2.14 2.10 2.15 2.18 2.11 2.09 2.03 2.06 2.04
Compound Leverage Factor
2.12 2.02 1.94 1.98 2.06 2.07 2.04 2.00 1.94 1.94 1.92
Debt to Total Capital
43.86% 45.38% 43.64% 43.70% 42.71% 43.84% 42.69% 41.83% 38.64% 40.86% 41.04%
Short-Term Debt to Total Capital
7.09% 7.88% 6.18% 5.94% 4.41% 5.48% 6.17% 4.88% 2.74% 3.37% 2.58%
Long-Term Debt to Total Capital
36.76% 37.50% 37.47% 37.76% 38.29% 38.36% 36.51% 36.96% 35.90% 37.49% 38.47%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.22% 0.23% 0.21% 0.17% 0.13% 0.13% 0.12% 0.13% 0.11% 0.11% 0.11%
Common Equity to Total Capital
55.93% 54.39% 56.15% 56.14% 57.16% 56.03% 57.19% 58.04% 61.26% 59.03% 58.85%
Debt to EBITDA
2.96 3.35 3.37 3.43 3.42 3.45 3.37 3.41 2.99 3.30 3.43
Net Debt to EBITDA
2.22 3.02 3.06 2.83 2.63 2.74 2.53 2.77 2.46 2.72 2.81
Long-Term Debt to EBITDA
2.48 2.77 2.89 2.96 3.07 3.02 2.88 3.02 2.78 3.02 3.22
Debt to NOPAT
4.51 5.30 5.33 5.42 5.33 5.56 5.38 5.43 4.70 4.96 5.07
Net Debt to NOPAT
3.40 4.77 4.84 4.47 4.10 4.43 4.04 4.41 3.86 4.09 4.15
Long-Term Debt to NOPAT
3.78 4.38 4.57 4.68 4.78 4.86 4.61 4.80 4.37 4.55 4.75
Altman Z-Score
3.66 3.75 3.65 3.55 3.66 3.93 3.82 4.06 3.89 3.67 3.23
Noncontrolling Interest Sharing Ratio
0.42% 0.42% 0.39% 0.35% 0.30% 0.32% 0.29% 0.26% 0.20% 0.21% 0.20%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.48 1.27 1.42 1.63 1.75 1.70 1.72 1.63 1.66 1.77 1.93
Quick Ratio
0.98 0.72 0.79 1.03 1.16 1.09 1.14 1.02 1.03 1.09 1.18
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
2,938 -1,064 -2,426 -2,821 -1,855 1,595 2,363 -1,435 163 -2,130 -3,593
Operating Cash Flow to CapEx
640.99% 161.28% 550.00% 907.52% 944.92% 364.72% 687.72% 859.52% 710.58% 206.57% 477.47%
Free Cash Flow to Firm to Interest Expense
10.92 -3.55 -7.44 -7.86 -4.76 4.39 6.68 -4.03 0.52 -7.03 -8.89
Operating Cash Flow to Interest Expense
12.96 2.43 4.72 6.72 9.55 3.45 5.54 6.08 10.38 2.39 3.46
Operating Cash Flow Less CapEx to Interest Expense
10.94 0.92 3.87 5.98 8.54 2.50 4.73 5.38 8.92 1.23 2.74
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.47 0.47 0.47 0.46 0.44 0.44 0.44 0.43 0.44 0.44 0.43
Accounts Receivable Turnover
5.58 5.54 5.52 5.41 5.25 5.36 5.31 5.10 5.23 5.24 5.23
Inventory Turnover
4.86 4.69 4.63 4.69 4.80 4.69 4.62 4.63 5.00 4.86 4.73
Fixed Asset Turnover
5.10 4.92 4.88 4.88 4.58 4.55 4.56 4.56 4.57 4.60 4.57
Accounts Payable Turnover
8.30 9.57 10.47 10.49 8.24 9.46 10.09 9.82 8.46 8.98 9.20
Days Sales Outstanding (DSO)
65.39 65.87 66.10 67.42 69.56 68.09 68.79 71.61 69.85 69.71 69.84
Days Inventory Outstanding (DIO)
75.16 77.76 78.80 77.77 75.97 77.80 78.96 78.78 72.97 75.11 77.23
Days Payable Outstanding (DPO)
43.95 38.13 34.86 34.80 44.31 38.57 36.16 37.19 43.14 40.64 39.68
Cash Conversion Cycle (CCC)
96.60 105.51 110.04 110.39 101.23 107.32 111.59 113.20 99.68 104.18 107.39
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
70,112 74,208 74,790 74,597 73,679 73,982 74,115 77,766 75,377 77,727 79,443
Invested Capital Turnover
0.63 0.60 0.60 0.60 0.60 0.57 0.57 0.56 0.58 0.57 0.56
Increase / (Decrease) in Invested Capital
-1,258 2,574 3,947 4,629 3,567 -226 -675 3,169 1,698 3,745 5,328
Enterprise Value (EV)
240,951 253,355 231,746 224,108 231,470 252,876 237,774 263,481 224,780 217,028 183,053
Market Capitalization
214,817 221,404 200,708 194,839 204,526 224,411 211,089 234,706 198,988 188,691 154,123
Book Value per Share
$112.13 $109.64 $113.43 $117.45 $120.96 $119.15 $124.26 $128.25 $129.63 $130.92 $133.81
Tangible Book Value per Share
($37.38) ($48.92) ($43.96) ($39.76) ($36.12) ($37.63) ($31.25) ($36.64) ($30.85) ($32.94) ($31.49)
Total Capital
78,636 77,690 77,923 80,748 81,759 81,231 82,939 84,412 80,946 83,674 85,831
Total Debt
34,488 35,257 34,008 35,284 34,917 35,608 35,405 35,313 31,275 34,189 35,229
Total Long-Term Debt
28,909 29,135 29,194 30,489 31,308 31,157 30,284 31,197 29,061 31,370 33,015
Net Debt
25,964 31,775 30,875 29,133 26,837 28,358 26,582 28,668 25,705 28,242 28,839
Capital Expenditures (CapEx)
544 452 280 266 394 343 285 252 463 350 293
Debt-free, Cash-free Net Working Capital (DFCFNWC)
5,274 6,965 7,564 7,578 6,106 6,904 7,002 6,653 5,449 7,076 7,690
Debt-free Net Working Capital (DFNWC)
13,798 10,447 10,697 13,729 14,186 14,154 15,825 13,298 11,019 13,023 14,080
Net Working Capital (NWC)
8,219 4,325 5,883 8,934 10,577 9,703 10,704 9,182 8,805 10,204 11,866
Net Nonoperating Expense (NNE)
106 218 159 113 106 38 135 105 36 104 117
Net Nonoperating Obligations (NNO)
25,964 31,775 30,875 29,133 26,837 28,359 26,581 28,667 25,706 28,242 28,841
Total Depreciation and Amortization (D&A)
848 859 855 853 839 836 791 739 742 705 686
Debt-free, Cash-free Net Working Capital to Revenue
11.74% 15.90% 17.38% 17.45% 14.25% 16.25% 16.54% 15.70% 12.71% 16.49% 17.80%
Debt-free Net Working Capital to Revenue
30.72% 23.85% 24.58% 31.62% 33.10% 33.31% 37.37% 31.39% 25.70% 30.36% 32.58%
Net Working Capital to Revenue
18.30% 9.87% 13.52% 20.58% 24.68% 22.83% 25.28% 21.67% 20.53% 23.79% 27.46%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$4.02 $3.34 $3.53 $4.44 $4.21 $3.47 $4.05 $4.26 $4.80 $3.99 $4.28
Adjusted Weighted Average Basic Shares Outstanding
392M 386M 386M 386M 386M 382M 382M 382M 382M 378M 378M
Adjusted Diluted Earnings per Share
$4.01 $3.32 $3.51 $4.42 $4.20 $3.46 $4.04 $4.25 $4.78 $3.98 $4.28
Adjusted Weighted Average Diluted Shares Outstanding
394M 388M 388M 388M 388M 384M 383M 384M 383M 379M 378M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
385.43M 385.72M 385.95M 386.37M 381.31M 381.72M 382.00M 382.50M 377.26M 377.49M 377.61M
Normalized Net Operating Profit after Tax (NOPAT)
1,729 1,618 1,697 1,890 1,786 1,393 1,759 1,776 2,072 1,708 1,813
Normalized NOPAT Margin
15.10% 15.11% 15.88% 17.87% 16.41% 13.46% 16.69% 16.76% 18.18% 16.48% 16.70%
Pre Tax Income Margin
15.52% 12.73% 13.38% 16.69% 15.98% 15.36% 16.74% 16.44% 17.03% 15.63% 15.74%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
7.05 5.06 4.84 5.23 4.67 4.61 5.16 5.12 6.40 5.67 4.49
NOPAT to Interest Expense
6.24 5.03 4.66 5.04 4.39 3.77 4.77 4.87 5.87 5.33 4.30
EBIT Less CapEx to Interest Expense
5.03 3.55 3.98 4.49 3.66 3.66 4.35 4.41 4.94 4.52 3.77
NOPAT Less CapEx to Interest Expense
4.22 3.53 3.81 4.30 3.38 2.83 3.96 4.16 4.41 4.18 3.57
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
6.54% 7.78% 8.51% 8.51% 8.78% 9.03% 8.97% 9.32% 9.20% 9.16% 9.27%
Augmented Payout Ratio
49.64% 74.09% 78.36% 76.04% 59.16% 59.08% 57.48% 58.34% 72.31% 55.19% 54.84%

Key Financial Trends

Thermo Fisher Scientific (NYSE: TMO) has demonstrated consistent revenue growth over the past several years, with quarterly total revenues increasing from approximately $10.7 billion in Q1 2023 to about $10.9 billion in Q2 2025. Gross profit margins remain healthy, typically around 40% to 45%, indicating efficient cost management on the cost of revenue.

Earnings have shown a positive trend, with net income continuing operations increasing from about $1.29 billion in Q1 2023 to approximately $1.62 billion in Q2 2025. Diluted EPS has also trended upwards, from $3.32 in Q1 2023 to $4.28 in Q2 2025, signaling improved profitability per share. The company maintains a consistent dividend, holding steady around $0.39 to $0.43 per share quarterly, underlining its commitment to returning cash to shareholders.

On the balance sheet, total assets have grown from around $94.7 billion in Q1 2023 to approximately $101.2 billion in Q2 2025, driven by growth in both current and noncurrent assets. Goodwill and intangible assets remain substantial components of total assets, reflecting ongoing investments and acquisitions.

Total liabilities have also increased from around $51.4 billion in Q1 2023 to about $50.6 billion in Q2 2025, showing relatively stable leverage levels. Long-term debt has grown but remains balanced against equity, with total equity rising from approximately $42.3 billion in Q1 2023 to over $50.5 billion in Q2 2025, suggesting solid capitalization.

Operating cash flow consistently generates positive cash, improving from around $729 million in Q1 2023 to approximately $1.4 billion in Q2 2025, supporting the company's operational needs and capital investments. Capital expenditures and investments have fluctuated but form a routine part of their capital allocation strategy.

Key takeaways impacting Thermo Fisher Scientific's stock:

  • Consistent revenue growth with total revenue rising to $10.85 billion in Q2 2025, up from about $10.7 billion in early 2023.
  • Improving net income and EPS, with net income increasing to $1.62 billion and diluted EPS reaching $4.28 by Q2 2025.
  • Strong operating cash flow growth, supporting business operations and investments.
  • Rising total equity to $50.5 billion in Q2 2025, indicating solid financial footing and capitalization.
  • Stable gross profit margins around 40-45%, implying consistent cost control but limited margin expansion.
  • Continued significant goodwill and intangible assets, reflecting ongoing acquisition strategy with associated integration risks.
  • Maintained quarterly cash dividends, reinforcing shareholder return policy but limiting cash flexibility for other uses.
  • Long-term debt increased to $33 billion by Q2 2025, indicating rising financial leverage that warrants monitoring.
  • Fluctuating changes in operating assets and liabilities have sometimes pressured operating cash flow.
  • Restructuring charges remain present, peaking at $228 million in Q4 2024, suggesting ongoing business adjustment costs.

Overall, Thermo Fisher Scientific presents a stable growth profile with improving profitability and cash generation. The company balances its investment in growth—particularly intangible assets and acquisitions—with shareholder returns. Investors should monitor debt levels and restructuring costs for potential headwinds.

09/14/25 04:55 AM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About Thermo Fisher Scientific's Financials

When does Thermo Fisher Scientific's fiscal year end?

According to the most recent income statement we have on file, Thermo Fisher Scientific's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Thermo Fisher Scientific's net income changed over the last 10 years?

Thermo Fisher Scientific's net income appears to be on an upward trend, with a most recent value of $6.34 billion in 2024, rising from $1.89 billion in 2014. The previous period was $5.96 billion in 2023. View Thermo Fisher Scientific's forecast to see where analysts expect Thermo Fisher Scientific to go next.

What is Thermo Fisher Scientific's operating income?
Thermo Fisher Scientific's total operating income in 2024 was $7.34 billion, based on the following breakdown:
  • Total Gross Profit: $17.70 billion
  • Total Operating Expenses: $10.36 billion
How has Thermo Fisher Scientific's revenue changed over the last 10 years?

Over the last 10 years, Thermo Fisher Scientific's total revenue changed from $16.89 billion in 2014 to $42.88 billion in 2024, a change of 153.9%.

How much debt does Thermo Fisher Scientific have?

Thermo Fisher Scientific's total liabilities were at $47.65 billion at the end of 2024, a 8.2% decrease from 2023, and a 113.6% increase since 2014.

How much cash does Thermo Fisher Scientific have?

In the past 10 years, Thermo Fisher Scientific's cash and equivalents has ranged from $452.10 million in 2015 to $10.33 billion in 2020, and is currently $4.01 billion as of their latest financial filing in 2024.

How has Thermo Fisher Scientific's book value per share changed over the last 10 years?

Over the last 10 years, Thermo Fisher Scientific's book value per share changed from 51.60 in 2014 to 129.63 in 2024, a change of 151.2%.



This page (NYSE:TMO) was last updated on 9/14/2025 by MarketBeat.com Staff
From Our Partners